MGC Pharmaceuticals Ltd.

Compliance Statement - Share Issues in 2021

16 February 2022

ASX, LSE: MXC

In addition to the Market Release on 10 February 2022 advising that MGC Pharmaceuticals Ltd was applying for the admission of new share issues completed in 2021 to the FCA's Official List, and for trading on the Main Market of the LSE from 8:00am (GMT) on 16 February 2022, the Company advises that of the 194,010,702 share issues completed in 2021:

1.     116,825,562 shares were issued on conversion of convertible notes and the exercise of options

2.     62,731,037 shares were issued as purchase consideration in relation to the acquisition of MediCaNL Inc

3.     5,650,000 shares were issued on the exercise of securities granted under the Company's Employee Share Scheme

4.     8,804,103 shares were issued as consideration under a contract of service.

--Ends--

Authorised for release by the Chairman, for further information please contact:

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytomedicines to patients globally.  The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline. 

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.  

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. 

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma